The One-Year Outcome of LuX-Valve Plus TRAVEL II Study was Officially Released at TCT 2024 | PR Newswire [Video]

, /PRNewswire/ — Jenscare Scientific Co., Ltd. (“Jenscare” or the “Company”) (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, has just released the 1-year outcome of LuX-Valve Plus TRAVEL II study at 2024 Transcatheter Cardiovascular Therapeutics Conference (TCT 2024) on October 29^th in Washington, D.C., U.S.. TRAVEL II study results showed that LuX-Valve Plus system is safe and effective in achieving short delivery times, low composite event rates, significant TR reduction and improvement in functional and QoL (quality of life) metrics at 1 year.

TRAVEL II aims to evaluate the long-term safety and efficacy of LuX-Valve Plus in the application on patients with severe tricuspid regurgitation and high surgical risk. The clinical trial enrolled 96 patients from 15 centers in China. The average age of the patients was 71.35 years old with an average STS score of 9.09%. 37.5% of the patients …